**Quarterly activities report for January – March 2025**

The quarterly activities include details of monitoring and compliance activities by the Office of the Gene Technology Regulator (OGTR) during the quarter.

**Monitoring of GMO Dealings involving Intentional Release (DIR)**

During the quarter, the OGTR did not inspect any GM plant field trial sites. The OGTR inspected **one** organisation conducting GMO dealings involving intentional release relating to protein fermentation and production.

Table 1 – Summary of inspection activities of DIR licences for the January – March 2025 quarter.

| **Licence holder** | **Licence Number** |
| --- | --- |
| Cauldron Molecules Pty Ltd | DIR-200 |

**Monitoring of GMO Dealings Not involving Intentional Release (DNIR), certified facilities and DIR clinical trials**

During the quarter, the OGTR inspected **six** organisations holding certified facilities (**Table 2**), **two** of which were also undertaking GMO dealings authorised by a DNIR licence (**Table 3**)**.**

Table 2 – Summary of organisations and facility types that the OGTR inspected for the January – March 2025 quarter.

| **Organisation** | **Physical Containment (PC) level** | **Number of facilities monitored** |
| --- | --- | --- |
| University of Tasmania | PC2 Laboratory  PC2 Animal Facility  PC2 Aquatic  PC2 Invertebrate  PC2 Plant Facility | 1  2  1  1  3 |
| The Walter and Eliza Hall Institute of Medical Research (WEHI) | PC2 Laboratory  PC2 Animal Facility  PC2 Invertebrate | 5  1  1 |
| University of New South Wales | PC2 Laboratory  PC2 Animal Facility | 11  1 |
| Griffith University | PC2 Laboratory  PC2 Animal Facility  PC3 Laboratory  PC3 Animal Facility | 3  1  1  1 |
| QIMR Berghofer | PC2 Laboratory  PC2 Invertebrate  PC2 Aquatic | 10  1  1 |
| Royal Brisbane and Women’s Hospital | PC2 Laboratory  PC2 Animal | 1  1 |
| **Total** |  | **47** |

Table 3 – Summary of inspection activities for DNIR licences for the January – March 2025 quarter.

| **Licence holder** | **Licence number** |
| --- | --- |
| Griffith University | DNIR-617 |
| The Walter and Eliza Hall Institute of Medical Research (WEHI) | DNIR-649 |

**Practice Reviews, Audits and Investigations**

The Monitoring and Compliance section may initiate Practice Reviews in response to observations made during earlier monitoring activities, or to follow up incident reports. The objective is to determine if licence conditions can be, and are being, effectively implemented.

During the January – March 2025 quarter, the OGTR continued its program of practice reviews, undertaking meetings with:

* The University of Tasmania (DIR-195) - Trial of a genetically modified vaccine against devil facial tumour disease in Tasmanian devils, as part of the practice review into the ‘*Preparedness of accredited organisations to undertake licensed dealings involving intentional release*’.

During the January – March 2025 quarter the OGTR continued an audit of Monash University in Victoria.

Audit findings will be reported in the Gene Technology Regulator’s Annual Report once the respective audit has been completed.

Audits of seed breeding companies were conducted in Queensland reviewing their quality assurance processes as part of the OGTR Low Level Presence Strategy. These audits of the industry are ongoing and will be reported in the Annual Report.

During the January – March 2025 quarter the OGTR did not commence any investigations.

**Monitoring and Compliance Findings**

Findings from routine monitoring, auditing, investigations, and related enforcement activities, will be provided in the Regulator’s Annual Report in accordance with section 136 of the *Gene Technology Act 2000*.